HMGA2 and endometrial carcinoma: Given that most endometrial carcinomas are adenocarcinomas where immunotherapy-chemotherapy combinations constitute first-line therapy for advanced/recurrent disease (1), we pharmacologically profiled HMGA2 using GDSC database.